VYNE News and Press, VYNE Therapeutics Inc Com From 04/07/21

VYNE has two approved products and a late-stage asset. The company has adequate cash after the recent offering. The company is a leader in the acne and rosacea markets. For further details see: VYNE Therapeutics: Rapidly Progressing In The Dermatology Market

Innovation, R&D and an aging population are long-term secular trends that will provide a tailwind to the biotechnology sector. The Insurgent AI Deep Innovation Model uses Deep Learning and secular tailwinds to generate alpha. Evaluating investment strategies is challenging, es...

The following slide deck was published by VYNE Therapeutics Inc. in conjunction with this event. For further details see: VYNE Therapeutics (VYNE) Investor Presentation - Slideshow

Evofem Biosciences EVFM -25% on Q4 earnings release.Super League Gaming (SLGG) -19%.GSX Techedu GSX -15% on Q4 earnings release.T2 Biosystems TTOO -10% on Q4 earnings release.Senseonics Holdings SENS -9% on Q4 earnings release.Aerpio Pharmaceuticals ARP...

Foamix Pharmaceuticals Ltd (FOMX) Q4 2020 Earnings Conference Call March 4, 2021 08:30 ET Company Participants Michael Wood - Investor Relations Dave Domzalski - President and Chief Executive Officer Matt Wiley - Chief Commercial Officer Andrew Saik - Chief Financial Officer Iain Stuart - Chi...

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C....

Image source: The Motley Fool. VYNE Therapeutics Inc. (NASDAQ: VYNE) Q4 2020 Earnings Call Mar 04, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: VYNE Therapeutics Inc. (VYNE) Q4 2020 Earnings Call Transcript

VYNE Therapeutics (VYNE): Q4 Non-GAAP EPS of -$0.43 beats by $0.08; GAAP EPS of -$0.55 misses by $0.09.Revenue of $4.29M (+2964.3% Y/Y) misses by $0.69M.Shares -2.7% PM.Press Release For further details see: VYNE Therapeutics EPS beats by $0.08, misses on revenue

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update. “We conti...

BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and participate at the Cowen 41 st Annual Health Care Conference....